Literature DB >> 24191300

Functional roles for C5a and C5aR but not C5L2 in the pathogenesis of human and experimental cerebral malaria.

Hani Kim1, Laura K Erdman, Ziyue Lu, Lena Serghides, Kathleen Zhong, Aggrey Dhabangi, Charles Musoke, Craig Gerard, Christine Cserti-Gazdewich, W Conrad Liles, Kevin C Kain.   

Abstract

The host immune response plays an important role in the onset and progression of cerebral malaria (CM). The complement system is an essential component of the innate immune response to malaria, and its activation generates the anaphylatoxin C5a. To test the hypothesis that C5a signaling contributes to the pathogenesis of CM, we investigated a causal role for the C5a receptors C5aR and C5L2 in a mouse model of experimental CM (ECM) induced by Plasmodium berghei ANKA infection, and using a case-control design, we examined levels of C5a in plasma samples from Ugandan children presenting with CM or uncomplicated malaria (UM). In the ECM model, C5aR(-/-) mice displayed significantly improved survival compared to their wild-type (WT) counterparts (P = 0.004), whereas C5L2(-/-) mice showed no difference in survival from WT mice. Improved survival in C5aR(-/-) mice was associated with reduced levels of the proinflammatory cytokines tumor necrosis factor (TNF) and gamma interferon (IFN-γ) and the chemokine, monocyte chemoattractant protein 1 (MCP-1) (CCL2). Furthermore, endothelial integrity was enhanced, as demonstrated by increased levels of angiopoietin-1, decreased levels of angiopoietin-2 and soluble ICAM-1, and decreased Evans blue extravasation into brain parenchyma. In the case-control study, the median levels of C5a at presentation were significantly higher in children with CM versus those in children with UM (43.7 versus 22.4 ng/ml; P < 0.001). These findings demonstrate that C5a is dysregulated in human CM and contributes to the pathogenesis of ECM via C5aR-dependent inflammation and endothelial dysfunction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24191300      PMCID: PMC3911851          DOI: 10.1128/IAI.01246-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  65 in total

Review 1.  Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster.

Authors: 
Journal:  Trans R Soc Trop Med Hyg       Date:  2000-04       Impact factor: 2.184

2.  Generation of C5a by phagocytic cells.

Authors:  Markus Huber-Lang; Ellen M Younkin; J Vidya Sarma; Niels Riedemann; Stephanie R McGuire; Kristina T Lu; Robin Kunkel; John G Younger; Firas S Zetoune; Peter A Ward
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

3.  Role of ICAM-1 (CD54) in the development of murine cerebral malaria.

Authors:  N Favre; C Da Laperousaz; B Ryffel; N A Weiss; B A Imhof; W Rudin; R Lucas; P F Piguet
Journal:  Microbes Infect       Date:  1999-10       Impact factor: 2.700

4.  The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74).

Authors:  Stuart A Cain; Peter N Monk
Journal:  J Biol Chem       Date:  2001-12-31       Impact factor: 5.157

Review 5.  Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria.

Authors:  Nicholas H Hunt; Georges E Grau
Journal:  Trends Immunol       Date:  2003-09       Impact factor: 16.687

6.  C5L2, a nonsignaling C5A binding protein.

Authors:  Shoji Okinaga; Dubhfeasa Slattery; Alison Humbles; Zsusanna Zsengeller; Olivier Morteau; Michele Bennett Kinrade; Robbin M Brodbeck; James E Krause; Hye-Ryun Choe; Norma P Gerard; Craig Gerard
Journal:  Biochemistry       Date:  2003-08-12       Impact factor: 3.162

7.  Cytokine and chemokine responses in a cerebral malaria-susceptible or -resistant strain of mice to Plasmodium berghei ANKA infection: early chemokine expression in the brain.

Authors:  Syarifah Hanum P; Masashi Hayano; Somei Kojima
Journal:  Int Immunol       Date:  2003-05       Impact factor: 4.823

8.  Differentiating the pathologies of cerebral malaria by postmortem parasite counts.

Authors:  Terrie E Taylor; Wenjiang J Fu; Richard A Carr; Richard O Whitten; Jeffrey S Mueller; Nedson G Fosiko; Susan Lewallen; N George Liomba; Malcolm E Molyneux; Jeffrey G Mueller
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

9.  Systemic release of high mobility group box 1 (HMGB1) protein is associated with severe and fatal Plasmodium falciparum malaria.

Authors:  Sarah J Higgins; Katharine Xing; Hani Kim; Dylan C Kain; Feng Wang; Aggrey Dhabangi; Charles Musoke; Christine M Cserti-Gazdewich; Kevin J Tracey; Kevin C Kain; W Conrad Liles
Journal:  Malar J       Date:  2013-03-19       Impact factor: 2.979

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  21 in total

1.  Complement 5a receptor-mediated neutrophil dysfunction is associated with a poor outcome in sepsis.

Authors:  Ruonan Xu; Fang Lin; Chunmei Bao; Huihuang Huang; Chengcheng Ji; Siyu Wang; Lei Jin; Lijian Sun; Ke Li; Zheng Zhang; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2015-03-02       Impact factor: 11.530

2.  Complement factor C5 but not C3 contributes significantly to hydrosalpinx development in mice infected with Chlamydia muridarum.

Authors:  Zhangsheng Yang; Turner Conrad; Zhou Zhou; Jianlin Chen; Pavel Dutow; Andreas Klos; Guangming Zhong
Journal:  Infect Immun       Date:  2014-05-19       Impact factor: 3.441

Review 3.  Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.

Authors:  David S Fedson
Journal:  Ann Transl Med       Date:  2016-11

4.  T Cell Expression of C5a Receptor 2 Augments Murine Regulatory T Cell (TREG) Generation and TREG-Dependent Cardiac Allograft Survival.

Authors:  Divya A Verghese; Markus Demir; Nicholas Chun; Miguel Fribourg; Paolo Cravedi; Ines Llaudo; Trent M Woodruff; Pragya Yadav; Sergio A Lira; M Edward Medof; Peter S Heeger
Journal:  J Immunol       Date:  2018-02-07       Impact factor: 5.422

Review 5.  Genetic analysis of cerebral malaria in the mouse model infected with Plasmodium berghei.

Authors:  Sabrina Torre; David Langlais; Philippe Gros
Journal:  Mamm Genome       Date:  2018-06-19       Impact factor: 2.957

6.  THEMIS is required for pathogenesis of cerebral malaria and protection against pulmonary tuberculosis.

Authors:  Sabrina Torre; Sebastien P Faucher; Nassima Fodil; Silayuv E Bongfen; Joanne Berghout; Jeremy A Schwartzentruber; Jacek Majewski; Mark Lathrop; Andrea M Cooper; Silvia M Vidal; Philippe Gros
Journal:  Infect Immun       Date:  2014-12-01       Impact factor: 3.441

7.  Complement C5-deficient mice are protected from seizures in experimental cerebral malaria.

Authors:  Susan C Buckingham; Theresa N Ramos; Scott R Barnum
Journal:  Epilepsia       Date:  2014-11-10       Impact factor: 5.864

8.  USP15 regulates type I interferon response and is required for pathogenesis of neuroinflammation.

Authors:  Sabrina Torre; Maria J Polyak; David Langlais; Nassima Fodil; James M Kennedy; Irena Radovanovic; Joanne Berghout; Gabriel A Leiva-Torres; Connie M Krawczyk; Subburaj Ilangumaran; Karen Mossman; Chen Liang; Klaus-Peter Knobeloch; Luke M Healy; Jack Antel; Nathalie Arbour; Alexandre Prat; Jacek Majewski; Mark Lathrop; Silvia M Vidal; Philippe Gros
Journal:  Nat Immunol       Date:  2016-10-10       Impact factor: 25.606

9.  C5a alters blood-brain barrier integrity in a human in vitro model of systemic lupus erythematosus.

Authors:  Supriya D Mahajan; Neil U Parikh; Trent M Woodruff; James N Jarvis; Molly Lopez; Teresa Hennon; Patrick Cunningham; Richard J Quigg; Stanley A Schwartz; Jessy J Alexander
Journal:  Immunology       Date:  2015-07-15       Impact factor: 7.397

Review 10.  Desperately Seeking Therapies for Cerebral Malaria.

Authors:  Brittany A Riggle; Louis H Miller; Susan K Pierce
Journal:  J Immunol       Date:  2020-01-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.